MASSACHUSETTS GENERAL HOSPITAL

Dr. Alya A. Arabi from United Arab Emirates University has been granted four patents spanning computational drug design and medical device development.

Researchers from MIT, Massachusetts General Hospital, and Boston University propose a novel "Fund of Adaptive Royalties" (FAR) that finances half the cost of adaptive platform trials in exchange for future drug royalties.

A real-world study by Mass General Brigham's PETAL Consortium demonstrated that the combination of duvelisib and romidepsin achieved a 61% overall response rate in 38 patients with relapsed/refractory T-cell lymphomas.

Alzamend Neuro completed a $5 million private placement months ahead of schedule to fund five Phase II clinical trials of AL001 "Lithium in Brain" studies at Massachusetts General Hospital.

Penumbra has completed enrollment of 100 patients in the pivotal STORM-PE randomized controlled trial, comparing computer assisted vacuum thrombectomy plus anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism.

Multiple studies presented at MAD-ID 2025 demonstrate fidaxomicin's superior efficacy over vancomycin in preventing C. difficile infection recurrence among high-risk patient populations.

Dr. Erin E. Mauney at Massachusetts General Hospital is conducting the first clinical trial examining psilocybin's effects on treatment-resistant irritable bowel syndrome (IBS).

TPN-101, a first-in-class LINE-1 reverse transcriptase inhibitor, has been selected for inclusion in the Phase 2/3 HEALEY ALS Platform Trial based on promising Phase 2 data.

PSMA PET imaging has revolutionized prostate cancer detection and management, particularly in biochemical recurrence settings, with multiple FDA-approved agents now available including gallium-68 PSMA-11, piflufolastat F 18, and flotufolastat F 18.

Mythic Therapeutics will present updated dose escalation data from its Phase 1 KisMET-01 study of MYTX-011, a cMET-targeting antibody-drug conjugate, at the 2025 ASCO Annual Meeting.